AbbVie Inc. (ABBV) Risk Factors

Health CareLatest 10-K filed Feb 20, 2026Source: SEC EDGAR

WealthWire extracted and classified 32 risk factors from AbbVie Inc.’s latest SEC filing, mapping each to a standardized risk taxonomy so they can be compared across every company and sector. The breakdown below shows how those disclosures distribute across risk categories.

Recent key developments

Concrete developments — dated events, named agreements and instruments, legal proceedings — that AbbVie Inc. surfaced in its latest filing.

  • In August 2023, CMS selected Imbruvica for government-set prices in Medicare Part D beginning January 1, 2026.August 2023
  • In January 2025, CMS selected Vraylar and Linzess for government-set prices in Medicare Part D beginning January 1, 2027.January 2025
  • In January 2026, Botox was selected for government-set prices in Medicare Parts B and D beginning January 1, 2028.January 2026
  • In January 2026, AbbVie entered a voluntary agreement with the U.S. government to provide pricing concessions and U.S.-based R&D and capital investments in exchange for tariff exemptions and future pricing mandate exemptions during a three-year period.January 2026
  • In 2025, Skyrizi and Rinvoq each represented greater than 10% of total net revenues, and in aggregate accounted for approximately 42% of total net revenues.2025
  • Net revenues outside the United States were approximately 24% of AbbVie's total net revenues in 2025.2025
  • In 2025, McKesson Corporation, Cardinal Health, Inc., and Cencora, Inc. accounted for substantially all of AbbVie's U.S. pharmaceutical product sales.2025
  • As of December 31, 2025, carrying value of developed product rights and other intangible assets was $52.6 billion, and goodwill was $35.6 billion.December 31, 2025

Go deeper on ABBV

This page shows the category breakdown of the latest filing. The WealthWire API and dashboard add the full risk-factor text, multi-year trends, sector comparisons, and CSV export — for ABBV and every other S&P 500 company.